MedTrace Logo

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

NCT00354302 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 497

Last updated 2020-04-02

No results posted yet for this study

Summary

RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably.

PURPOSE: This phase III trial is studying bone mineral density in postmenopausal women with primary breast cancer who are receiving treatment on clinical trial CAN-NCIC-MA27.

Conditions

Interventions

DIETARY_SUPPLEMENT

calcium carbonate

DIETARY_SUPPLEMENT

calcium citrate

DIETARY_SUPPLEMENT

cholecalciferol

DRUG

alendronate sodium

DRUG

calcium gluconate

DRUG

risedronate sodium

OTHER

laboratory biomarker analysis

PROCEDURE

dual x-ray absorptometry

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • North Central Cancer Treatment Group

    collaborator NETWORK

  • SWOG Cancer Research Network

    collaborator NETWORK

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Paul E. Goss, MD, PhD · Massachusetts General Hospital

  • James N. Ingle, MD · Mayo Clinic

  • Dawn Hershman, MD · Herbert Irving Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-24
Primary Completion
2011-03-31
Completion
2012-01-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354302 on ClinicalTrials.gov